Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
about
Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitusConcentrated insulins: the new basal insulinsConcepts and clinical use of ultra-long basal insulinInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesMechanisms of hypoglycemia unawareness and implications in diabetic patientsCardiovascular effects of basal insulinsModern basal insulin analogs: An incomplete storyPatient safety and minimizing risk with insulin administration - role of insulin degludecUpdate on the treatment of type 2 diabetes mellitusPharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.A review of the pharmacological properties of insulin degludec and their clinical relevance.Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinicalInsulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsIDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetesA 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trialEffect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.Insulin therapy in people with type 2 diabetes: opportunities and challenges?Management of type 2 diabetes mellitus in older patients: current and emerging treatment options.Insulin degludec: a significant advancement in ultralong-acting Basal insulin.Insulin degludec: pharmacokinetic properties in subjects with hepatic impairmentInsulin degludec: pharmacokinetics in patients with renal impairment.Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
P2860
Q24194881-27CEC996-3CA7-4AFC-9C8D-999D20A9EF6BQ26750438-7624317B-17A8-470F-8111-68116995B24EQ26770354-55B1330A-99A0-452C-8587-588CC592F453Q26777076-8EC678A8-F17C-4C30-9A3D-783F343D8C18Q26778763-24C7941B-8987-4983-BFBD-E6E08422FD92Q26784381-7C50FAA7-CD63-4E51-B8C6-57A7948F885EQ26799608-575A8606-E0F9-4983-B52E-60C894BF45CEQ26800249-E9776574-554C-45FF-B4A6-232F7300A04AQ27015047-BE694BE2-DE3B-4E65-9833-611BA1208836Q27025548-B787EE90-EAC4-48A4-A6C7-867B40C9A4CDQ28073342-5FA46C6F-37FF-46CD-BFB1-6F92EEB5DA31Q30244827-D96B28F8-79FD-4437-9B32-B106D157162EQ30978373-6CCE36C9-5E0B-457B-BA5D-6421FD9D0EABQ31152059-2165FC37-DF98-44B7-BBB0-47E9630A8C28Q31154873-D0E16CA2-1801-4DDD-9052-FB7777A76053Q33607759-FC013686-E8E3-4C20-8B92-F8E67886EBD5Q34436383-0B25820D-3126-4A29-9153-CCCD27B4FE52Q34691408-81F2B606-70E2-4607-A7FB-F1F3634CC95AQ34726423-BD0FC354-3B02-4B62-8B65-2F724716C805Q34981168-C15A8652-37B3-4971-B5DE-F27441450E95Q35666228-0A199422-427E-49AA-98C6-2B68F6DBF97AQ36158944-C919E21B-F995-4377-9B7E-058D01935625Q36285880-A768938A-9485-4AA8-9638-A353F5848A32Q36366184-BD625C13-9403-4C29-ADBD-EBA60EA860E6Q36629179-1D354C30-1BF6-46FE-8083-19B5AD59001CQ36637960-DC6A8D10-63F7-4DC0-AA52-D86B09812FBCQ36638917-58A82EC6-61EC-4F5D-B15F-DD4669F78B67Q36924024-87899CAC-3813-4D35-84D1-C3A36034728AQ36971833-FA5946E0-2C36-4C1D-91C2-29ABFA10B2AFQ37227385-2C9863AA-6C44-4346-ABF3-DB8A26BDD944Q37321746-F9A09B6C-F878-4EF9-B794-69373D904FA7Q37344032-218B5596-FD25-4CC6-9D7F-186E257CEC26Q37357320-E8B70F61-CCD9-48C2-8B5A-B1B5774B57FCQ37374117-8E071738-B6A0-49D0-8F6E-20618947C141Q37461707-CB3FC442-1BAC-430A-97C4-46E845466F8DQ37468429-337C0166-82A8-4636-8E06-F131521551A1Q37468486-40E4AC8D-9DD6-446F-ADC8-1E674CCAE68BQ37506417-FE61C7D3-C9D6-4FE8-A6BB-EACD77F45DB1Q37506526-285088A4-1AB2-4EFC-A221-B2F9B336D553Q37737461-3F94624F-2E1A-4A8E-B8D5-325462B040A8
P2860
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@en
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@nl
type
label
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@en
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@nl
prefLabel
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@en
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@nl
P2093
P2860
P921
P356
P1476
Hypoglycaemia risk with insuli ...... ta-analysis of phase 3 trials.
@en
P2093
H Mersebach
R E Ratner
S C L Gough
S Del Prato
P2860
P304
P356
10.1111/DOM.12032
P577
2012-12-03T00:00:00Z